Efficacy and Toxicity of Maintenance Pemetrexed Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-small-cell Non-squamous Carcinoma of the Lung

Kim, D. H.; Kinmond, A.; Gilani, S.; Giridharan, S.; Jegannathen, A.

doi:10.1515/fco-2015-0008

Cited by 1 publication

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer is the leading cause of cancer-related death worldwide with an estimated 1.6 million new cases diagnosed each year [1]. Non-small cell lung cancer (NSCLC) accounts for 80% of all cases of lung cancer, and is further divided into several subgroups as adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others with 65% to 75% of them having locally advanced or metastatic disease [2].…”

Section: Introductionmentioning

confidence: 99%

“…According to the American Society of Clinical Oncology and National Comprehensive Cancer Network (NCCN) guidelines, patients with a performance status of 0 or 1 have to be treated with a combination of 2 cytotoxic drugs in first-line therapy [3]. In patients with metastatic NSCLC of non-squamous histology, current guidelines recommend the combination of cisplatin and pemetrexed as first line induction treatment [1].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prospective Analysis of Patients Treated with Chemotherapy in Metastatic Adenocarcinoma of Lung—Single Centre Experience

Srinivasa¹,

Bhanu²,

Badarke³

et al. 2017

JCT

View full text Add to dashboard Cite

Background: Lung cancer is the leading cause of cancer-related death worldwide with an estimated 1.6 million new cases diagnosed each year. According to standard guidelines in NSCLC, the effectiveness of combined chemotherapy regimen comprises of pemetrexed and platinum, and very few reports are available in Indian population. This study shows the experience with pemetrexed and platinum combination chemotherapy in metastatic NSCLC in first line setting. Methods: Total 61 patients with following inclusion criteria were recruited such as: 1) PS of 1 and 2; 2) NSCLC of non-squamous histology; 3) locally advanced or metastatic disease at diagnosis; 4) should have received minimum 3 cycles of pemetrexed and platinum as first line treatment and or continued for 6 cycles; 5) EGFR/ALK mutated or EGFR/ALK unknown patients but must have received upfront chemo. Primary endpoint of the present study is to assess Disease Control Rate (DCR) (CR + PR + SD). Progression Free Survival, OS and Toxicity assessment were secondary endpoints. Results: The mean number of average chemotherapy cycles was found to be 4.38. The range of chemotherapy was 2 -6 cycles. Disease control rate, defined as (CR + PR + SD), was seen in 44 (72.1%) patients. (PR in 26 (42.62%), SD 18 (29.5%)), Progressive disease (PD) was observed in 17 (27.9%) patients. Overall study showed that patients had PFS of 9.414 months (95% CI 6.709 -12.120) and OS of 13.437 months (95% CI 10.721 -16.153). Conclusion: Pemetrexed and platinum combination is effective and well-tolerated chemotherapy regimen in patients with metastatic adenocarcinoma lung cancer patients. Pemetrexed and cisplatin may be more effective in particular. Early switch over to TKIs is preferred immediately after obtaining molecular subtype result.How to cite this paper: Srinivasa, B

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%